{"prompt": "['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', '11 References', 'Abadi M, Agarwal A, Barham P, et al. TensorFlow: large-scale Machine Learning on heterogeneous', 'distributed Systems. In arXiv:1605.08695. 2016', 'Andre T, Bensmaine MA, Louvet C, et al. Multicenter phase Il study of bimonthly high-dose', 'leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant', 'to the same leucovorin and fluorouracil regimen. J Clin Oncol, 1999; 17(11), 3560-3568.', 'Andre T, Louvet C, Maindrault-Goebel F, et al. CPT-11 (irinotecan) addition to bimonthly, high-dose', 'leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated', 'metastatic colorectal cancer. GERCOR. Eur J Cancer, 1999; 35(9), 1343-1347.', 'Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant', 'treatment for colon cancer. N Engl J Med 2004; 350(23): 2343-51.', 'Buitinck L, Louppe G, Blondel, et al. API design for machine learning software: experiences from', 'the scikit-learn project. European Conference on Machine Learning and Principles and Practices', 'of Knowledge Discovery in Databases, Prague. 2013.', \"Carpizo DR, D'Angelica M. Liver resection for metastatic colorectal cancer in the presence of\", 'extrahepatic disease. Lancet Oncol 2009; 10(8): 801-9.', 'Choti MA, Thomas M, Wong SL, et al. Surgical Resection Preferences and Perceptions among', 'Medical Oncologists Treating Liver Metastases from Colorectal Cancer. Ann Surg Oncol', '2016; 23(2): 375-81.', 'Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic', 'cancer. N Engl J Med 2011; 364(19): 1817-25.', 'Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for', 'Pancreatic Cancer. N Engl J Med 2018; 379(25): 2395-406.', 'Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus', 'bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated', 'overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.', 'Lancet Oncol 2015; 16(13): 1306-15.', 'Cremolini C, Casagrande M, Loupakis F, et al. Efficacy of FOLFOXIRI plus bevacizumab in liver-', 'limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo', 'Oncologico del Nord Ovest. Eur J Cancer 2017; 73:74-84.', 'de Gramont A, Vignoud J, Tournigand C, et al. Oxaliplatin with high-dose leucovorin and 5-', 'fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J', 'Cancer 1997; 33(2), 214-219.', 'Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in', '2006. Ann Oncol 2007; 18(3), 581-592.', 'Folprecht G, Gruenberger T, Bechstein W, et al. Survival of patients with initially unresectable', 'colorectal liver metastases treated with FOLFOXIcetuximab or FOLFIRI/cetuximab in a', 'multidisciplinary concept (CELIM study). Ann Oncol 2014; 25(5): 1018-25.', 'Garcia M, Jemal A, Ward E, et al. Global Cancer Facts & Figures 2007. Atlanta, GA; American Cancer', 'Society 2007.', 'Gonzalez M, Poncet A, Combescure C, et al. Risk factors for survival after lung metastasectomy in', 'colorectal cancer patients: a systematic review and meta-analysis. Ann Surg Oncol 2013;', '20(2): 572-9.', 'Grothey A, Sobrero AF, Shields AF, et al. Duration of Adjuvant Chemotherapy for Stage III Colon', 'Cancer. N Engl J Med 2018; 378(13): 1177-88.', 'Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus', 'bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3):', 'a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15(10): 1065-75.', 'Confidential', 'Page 70 of 79']['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', 'Howlader N, Krapcho M, Neyman N et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009', 'Populations); Bethesda M: National Cancer Institute 2011.', 'Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is', 'associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol', '2009; 27(22): 3677-83.', 'Luo LX, Yu ZY, Huang JW, Wu H. Selecting patients for a second hepatectomy for colorectal', 'metastases: an systemic review and meta-analysis. Eur J Surg Oncol 2014; 40(9): 1036-48.', 'Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for', \"metastatic colorectal cancer. N Engl J Med 2014; '11(17): 1609-18.\", 'Maindrault-Goebel F, Louvet C, Andre T, et al. Oxaliplatin added to the simplified bimonthly', 'leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal', 'cancer (FOLFOX6). GERCOR. Eur J Cancer 1999; 35(9), 1338-1342.', 'Maindrault-Goebel F, de Gramont A, Louvet C, et al. Evaluation of oxaliplatin dose intensity in', 'bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in', 'pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group', '(GERCOR). Ann Oncol 2000; 11(11), 1477-1483.', 'Maindrault-Goebel F, De Gramont A, Louvet C, et al. High-dose intensity oxaliplatin added to the', 'simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for', 'metastatic colorectal cancer (FOLFOX 7). European Journal of Cancer 2001; 37(8), 1000-1005.', 'Mitry E, Fields AL, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of', 'metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol', '2008; 26(30): 4906-11.', 'Modest DP, Denecke T, Pratschke J, et al. Surgical treatment options following chemotherapy plus', 'cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3. Eur', 'J Cancer 2018; 88: 77-86.', 'Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery', 'versus surgery alone for resectable liver metastases from colorectal cancer (EORTC', 'Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371(9617): 1007-16.', 'Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative FOLFOX4 chemotherapy and surgery', 'versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983):', 'long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 2013; 14(12): 1208-', '15.', 'Patel D, Townsend AR, Karapetis C, et al. Is Survival for Patients with Resectable Lung Metastatic', 'Colorectal Cancer Comparable to Those with Resectable Liver Disease? Results from the', 'South Australian Metastatic Colorectal Registry. Ann Surg Oncol 2016; 23(11): 3616-22.', 'Primrose J, Falk S, Finch-Jones M, et al. Systemic chemotherapy with or without cetuximab in', 'patients with resectable colorectal liver metastasis: the New EPOC randomised controlled', 'trial. Lancet Oncol 2014;15(6):601-11', 'Rauch G, Brannath W, Bruckner M, et al. The Average Hazard Ratio - A Good Effect Measure for', 'Time-to-event Enppoints when the Proportional Hazard Assumption is Violated? Methods Inf', 'Med 2018; 57(3): 89-100.', 'Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland', 'e.V. (Hrsg). Krebs in Deutschland f\u00fcr 2015/2016. Berlin, 2019; 12. Ausgabe.', 'Saad ED, Katz A, Hoff PM, et al. Progression-free survival as surrogate and as true end point:', 'insights from the breast and colorectal cancer literature. Ann Oncol. 2010;21(1):7-12.', 'Schmiegel W, Buchberger B, Follmann M, et al. S3-Leitlinie - Kolorektales Karzinom. Z Gastroenterol', '2017; 55(12): 1344-498.', 'Confidential', 'Page 71 of 79']\n\n###\n\n", "completion": "END"}